<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Institute of Human Genetics</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/3058D691-F925-4E57-9B99-A0E6C0CC2030"><gtr:id>3058D691-F925-4E57-9B99-A0E6C0CC2030</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Burn</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B040D4DE-19CC-46E7-B6CF-4B74C2405920"><gtr:id>B040D4DE-19CC-46E7-B6CF-4B74C2405920</gtr:id><gtr:firstName>John</gtr:firstName><gtr:otherNames>Cummings</gtr:otherNames><gtr:surname>Mathers</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C57F521F-DBBE-4887-A1AA-1B146DA48F36"><gtr:id>C57F521F-DBBE-4887-A1AA-1B146DA48F36</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Timothy</gtr:otherNames><gtr:surname>Bishop</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0100496"><gtr:id>AD31B7B5-EFAC-444D-916C-0EAF8EC45FAA</gtr:id><gtr:title>Colorectal Adenoma/carcinoma Prevention Project 2 (CAPP2): RCT of aspirin and resistant starch in HNPCC(Lynch Syndrome)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0100496</gtr:grantReference><gtr:abstractText>Bowel cancer starts as a small lump or polyp, when a cell in the bowel wall grows out of control. This happens when several genes that control cell growth are faulty. Genes are codes that control how our bodies work, and can be damaged in a single cell by factors such as diet. Some families are more prone to bowel cancer because they have inherited a fault in a gene. People with Lynch syndrome, who don?t get many polyps but have a high chance of getting bowel cancer can be recognised using medical and family history and genetic testing. They have an error in a ?mismatch repair? gene whose job it is to ?spell check? other genes when they are copied to make new cells. When one of the mismatch repair genes fails, thousands of errors develop in other genes and this can lead to cancer. Taking regular aspirin seems to make people less likely to get bowel cancer and it also stops human and animal cancer cells growing in the laboratory. Aspirin seems to work particularly well on cells where the mismatch repair genes don?t work. Eating starchy food appears to reduce the risk of bowel cancer, especially if it reaches the bowel undigested, when it is called ?resistant starch?. Resistant starch is broken down in the bowel to make butyrate, a small molecule known to kill bowel cancer cells. Because aspirin has side effects, before we suggest people take it regularly or add starch to their food to prevent bowel cancer, we need to be sure that it really works. We have chosen to test it in people with Lynch syndrome because they are very likely to get polyps or cancer, and they are having regular bowel checks already. They are also very keen to help because it affects their families. The CAPP2 Study will test if aspirin and/or resistant starch can prevent polyps. We will ask 1,350 people with Lynch syndrome to take 2 tablets and 2 starch sachets daily for 2 to 4 years. The people in the study, and the researchers, will not know if the tablets and starch are active or harmless substitutes, so that we can be sure it is the treatments and not something else which is making the difference. We have recruited 450 people so far and will have a final answer by 2007.</gtr:abstractText><gtr:technicalSummary>A chemoprevention trial targeted at adults with Lynch syndrome, a monogenic form of colorectal cancer, this study has a randomised, placebo controlled factorial design. It will test the efficacy of two interventions for which there is strong indirect support; aspirin (600mg) and resistant starch(30g).A 3 year EU funded initial study has established the protocol and recruited 450, one third of the target number.</gtr:technicalSummary><gtr:fund><gtr:end>2008-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2002-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2308166</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>BBC RADIO 4 CASE NOTES</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>987D9CFA-6C96-409D-A337-C4A4DCA88CD0</gtr:id><gtr:impact>INTERVIEW ALONGSIDE THE FIRST RECRUIT TO THE TRIAL

WILL NOT BE BROADCAST UNTIL 2010</gtr:impact><gtr:outcomeId>365B82FB01F</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CAPP2 WEBSITE</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A662C611-EE6F-46A7-942E-0B2384C57E06</gtr:id><gtr:impact>OUTCOME OF TRIAL MADE AVAILABLE ON CAPP2 WEBSITE

WIDER APPRECIATION OF THIS NOVEL INTERNATIONAL CHEMOPREVENTION TRIAL</gtr:impact><gtr:outcomeId>D4E5D61ECCC</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1427802</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CTAAC</gtr:description><gtr:end>2020-08-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>C1297/A15934</gtr:fundingRef><gtr:id>A0799B1D-3C71-4917-BFA2-94F1DBD39A38</gtr:id><gtr:outcomeId>GDzvwnYRBBp</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>INTERNATIONAL CONSENSUS GROUP</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>DD4B8EAE-1EC7-48B3-9E4B-665E7F449FD5</gtr:id><gtr:outcomeId>95FB28D47D2</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7FE1D382-B6A8-436E-8A29-F824D1C9CEAD</gtr:id><gtr:title>Chemoprevention in Lynch syndrome.</gtr:title><gtr:parentPublicationTitle>Familial cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e24d64dffbf3f58693135eb1f052fc36"><gtr:id>e24d64dffbf3f58693135eb1f052fc36</gtr:id><gtr:otherNames>Burn J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1389-9600</gtr:issn><gtr:outcomeId>54609a5297f0e5.11049042</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0CC9E08-41C1-48EA-958B-815535A596AB</gtr:id><gtr:title>Prevalence of adenomas and hyperplastic polyps in mismatch repair mutation carriers among CAPP2 participants: report by the colorectal adenoma/carcinoma prevention programme 2.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fb578c9ee1215041cc322c8b31b4684"><gtr:id>5fb578c9ee1215041cc322c8b31b4684</gtr:id><gtr:otherNames>Liljegren A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>8226A2330F9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48971A93-D7FE-48B3-989A-B281C2ACE9DC</gtr:id><gtr:title>Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc0a28c9b60b6f961af01144125baaad"><gtr:id>dc0a28c9b60b6f961af01144125baaad</gtr:id><gtr:otherNames>Borthwick GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn><gtr:outcomeId>87A1F50E2E4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE58D9BC-E8C4-413A-BCB0-94F0DAFB7C71</gtr:id><gtr:title>Estimates of benefits and harms of prophylactic use of aspirin in the general population.</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95cbff3dcb07069b5196ff07035f2705"><gtr:id>95cbff3dcb07069b5196ff07035f2705</gtr:id><gtr:otherNames>Cuzick J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn><gtr:outcomeId>546234968efc40.43826812</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>910C0939-1F4D-457B-B061-FF035C39A5DF</gtr:id><gtr:title>Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e24d64dffbf3f58693135eb1f052fc36"><gtr:id>e24d64dffbf3f58693135eb1f052fc36</gtr:id><gtr:otherNames>Burn J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>8B5449A9EDA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE0527D7-87B6-462C-9A51-46C66B16564D</gtr:id><gtr:title>Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer).</gtr:title><gtr:parentPublicationTitle>Journal of medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/48e760e6709b308d5b263d1c802d2f41"><gtr:id>48e760e6709b308d5b263d1c802d2f41</gtr:id><gtr:otherNames>Vasen HF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-2593</gtr:issn><gtr:outcomeId>E03059C7AA5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C4EE1FF-84F9-4C04-84A6-16B8F61B5912</gtr:id><gtr:title>Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d50707391c992c544ddff87ad14d364"><gtr:id>0d50707391c992c544ddff87ad14d364</gtr:id><gtr:otherNames>M?ller P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>56d96fb48d3763.70755312</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CAF0EC3-F778-4F38-9D5D-B63DF910B0A9</gtr:id><gtr:title>Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8bae0e95d8ad25d0dbffb5c07abb21bc"><gtr:id>8bae0e95d8ad25d0dbffb5c07abb21bc</gtr:id><gtr:otherNames>Movahedi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>56d9710693b911.14073397</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D79E299-2A92-4791-89DF-CA91A517FB45</gtr:id><gtr:title>Cell kinetics and gene expression changes in colorectal cancer patients given resistant starch: a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1bf8d440bb2a4314165a4e602c147163"><gtr:id>1bf8d440bb2a4314165a4e602c147163</gtr:id><gtr:otherNames>Dronamraju SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>D1DB7FF9748</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8836F713-FA00-4DF5-8541-209A25F3BB2F</gtr:id><gtr:title>Germ line mutations of mismatch repair genes in hereditary nonpolyposis colorectal cancer patients with small bowel cancer: International Society for Gastrointestinal Hereditary Tumours Collaborative Study.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ed414e7a86f1529af5986a63254bb69"><gtr:id>2ed414e7a86f1529af5986a63254bb69</gtr:id><gtr:otherNames>Park JG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>E253C705FF4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>989A5266-0753-413E-BEDF-D9D5B027FD71</gtr:id><gtr:title>Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95cbff3dcb07069b5196ff07035f2705"><gtr:id>95cbff3dcb07069b5196ff07035f2705</gtr:id><gtr:otherNames>Cuzick J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>54609a50974b76.23854607</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE917DCD-D30C-4293-BD00-292F522625CC</gtr:id><gtr:title>Lynch syndrome: history, causes, diagnosis, treatment and prevention (CAPP2 trial).</gtr:title><gtr:parentPublicationTitle>Digestive diseases (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e24d64dffbf3f58693135eb1f052fc36"><gtr:id>e24d64dffbf3f58693135eb1f052fc36</gtr:id><gtr:otherNames>Burn J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0257-2753</gtr:issn><gtr:outcomeId>5460ba3cc3fe41.71794504</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A0FF0AC-9174-4067-AC5D-F850C5D5CB4A</gtr:id><gtr:title>MLH1 germline epimutations as a factor in hereditary nonpolyposis colorectal cancer.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4818723d479173ee006a00b0387477ec"><gtr:id>4818723d479173ee006a00b0387477ec</gtr:id><gtr:otherNames>Hitchins M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>E419583ECA8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4DA3D70A-ABBC-4161-9991-6A3A136CBE91</gtr:id><gtr:title>MLH1 Differential allelic expression in mutation carriers and controls.</gtr:title><gtr:parentPublicationTitle>Annals of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/20e2161932e2d0c016714c8c0f509a8c"><gtr:id>20e2161932e2d0c016714c8c0f509a8c</gtr:id><gtr:otherNames>Santibanez Koref M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0003-4800</gtr:issn><gtr:outcomeId>54609a51203f87.09975097</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1EFBB2A3-521B-4DC2-AF04-A5EDEA52587F</gtr:id><gtr:title>Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial.</gtr:title><gtr:parentPublicationTitle>Cancer prevention research (Philadelphia, Pa.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/929ae17d4c870625c33fc2cbe77a59aa"><gtr:id>929ae17d4c870625c33fc2cbe77a59aa</gtr:id><gtr:otherNames>Bertagnolli MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1940-6215</gtr:issn><gtr:outcomeId>54609a5071a9c2.33911253</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>393C89A9-CCE7-484B-9278-D4F5674E13FC</gtr:id><gtr:title>A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis.</gtr:title><gtr:parentPublicationTitle>Cancer prevention research (Philadelphia, Pa.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e24d64dffbf3f58693135eb1f052fc36"><gtr:id>e24d64dffbf3f58693135eb1f052fc36</gtr:id><gtr:otherNames>Burn J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1940-6215</gtr:issn><gtr:outcomeId>pm_16441_21_21543343</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15E8C431-F33F-460F-89C9-21522049E96A</gtr:id><gtr:title>Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e24d64dffbf3f58693135eb1f052fc36"><gtr:id>e24d64dffbf3f58693135eb1f052fc36</gtr:id><gtr:otherNames>Burn J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>54609a51ef2ce5.16092297</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4AE9C37B-4C25-48CA-B428-0DB9A3FED4F0</gtr:id><gtr:title>Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58b325ac5379b28d5b6434a807b12092"><gtr:id>58b325ac5379b28d5b6434a807b12092</gtr:id><gtr:otherNames>Mathers JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>pm_16441_21_23140761</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0100496</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>